Biolex filed for chapter 7 on July 3, according to news provider Triangle Business Journal. Investors had invested $190m in Biolex since it was founded in 1997, Triangle Business Journal said.
Biolex Therapeutics, a US-based healthcare company backed by healthcare company Johnson & Johnson’s corporate venturing unit, has reportedly filed for bankruptcy protection.
Biolex filed for chapter 7 on July 3, according to news provider Triangle Business Journal. Investors had invested $190m in Biolex since it was founded in 1997, Triangle Business Journal said.
Johnson & Johnson has a $3.8m claim, according to Triangle Business Journal citing Biolex’s Chapter 7 filing, and had an 11% stake in the company. Venture firms…
